ACS Chemical Biology
-
COX-2 ‘conjugate’ may slow growth of some tumors: study
More than a decade after the anti-inflammatory drugs Vioxx and Bextra were pulled from the market because of a heightened risk of heart attack and stroke in some patients, COX-2 inhibitors may be on the verge of a comeback, this time as anti-cancer agents. Read MoreJan 19, 2017
-
Schizophrenia ‘switches’ discovered
Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way. Read MoreSep 12, 2014